Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
23 avr. 2024 08h15 HE
|
Silo Pharma, Inc.
Intranasal Delivery of SPC-15 shows rapid and effective drug exposure for PTSD Therapy SARASOTA, FL, April 23, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”),...
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 avr. 2024 08h35 HE
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
20 mars 2024 08h30 HE
|
Silo Pharma, Inc.
Exclusive license for development, manufacturing, and commercialization in process Silo Pharma to file Pre-IND in first half 2024 SARASOTA, FL, March 20, 2024 (GLOBE NEWSWIRE) -- Silo Pharma,...
Global Post-traumatic Stress Disorder (PTSD) Drug Pipeline Landscape Report 2024 Featuring Tonix Pharmaceuticals, Pop Test Oncology, H. Lundbeck, Bionomics, and Alto Neuroscience
29 févr. 2024 11h06 HE
|
Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Post-traumatic Stress Disorder (PTSD) - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report...
MAPS Congratulates Lykos Therapeutics on Acceptance of New Drug Application for MDMA-Assisted Therapy for PTSD
09 févr. 2024 19h30 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The FDA has accepted Lykos Therapeutics' New Drug Application, supported by two decades of research incubated by MAPS, for MDMA-assisted therapy for PTSD.
electroCore Expands Intellectual Property Portfolio
09 janv. 2024 08h00 HE
|
electroCore, Inc.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
PTSD: The Brain Basis of Susceptibility - A Free Webinar from the Brain & Behavior Research Foundation
03 janv. 2024 09h04 HE
|
Brain & Behavior Research Foundation
New York, Jan. 03, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “PTSD: The Brain Basis of Susceptibility” on Tuesday, January 9, 2024, at...
Healis Therapeutics Announces Supply Agreement with CKD Bio to develop CKDB-501 for neuropsychiatric indications
02 janv. 2024 08h00 HE
|
Healis Therapeutics
NEWPORT BEACH, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics, a privately held biotechnology company, today announced it has entered into a supply agreement with CKD Bio Corporation...
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
13 déc. 2023 18h16 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
The first NDA submission for any psychedelic-assisted therapy has been submitted through a 30-year effort initiated and led by the nonprofit MAPS
The Virtual Trip Showcases Veterans Sessions from Psychedelic Science 2023 in Honor of Veterans Day
11 nov. 2023 01h46 HE
|
Multidisciplinary Association for Psychedelic Studies (MAPS)
Eight virtual conference sessions explore psychedelic research for Veterans including trauma support, federal backing, and a pilot study on Ibogaine